HeartLung Technologies, a pioneer in AI-driven preventive imaging, is celebrating a significant milestone in the field of medical innovation. The company is honoring its Scientific and Medical Advisor, Dr. Claudia Henschke, for her groundbreaking contributions to medicine. Dr. Henschke has been awarded the prestigious 2026 Jacobi Medallion, one of the most distinguished honors bestowed by the Icahn School of Medicine at Mount Sinai.
Dr. Henschke's recognition is a testament to her decades of pioneering work in lung cancer screening and diagnostic radiology. As the Director of the Early Lung and Cardiac Action Program and Professor in the Department of Diagnostic, Molecular, and Interventional Radiology at the Icahn School of Medicine, she has been instrumental in advancing low-dose CT screening for early lung cancer detection. Her efforts have not only transformed the medical community's approach to lung cancer screening but have also had a profound impact on patient outcomes.
One of her most notable achievements is the founding and leadership of the International Early Lung Cancer Action Program. This global collaboration brings together physicians and scientists to improve lung cancer screening, early detection, and patient outcomes worldwide. Dr. Henschke's work has emphasized the clinical importance of detecting lung cancer at an early stage, making it more treatable.
Her influence extends beyond the field of lung cancer screening. Dr. Henschke has authored over 400 peer-reviewed publications, contributed to major national and international lung screening initiatives, and trained more than 80 physician researchers. Her leadership has significantly impacted preventive imaging, early lung cancer detection, and the broader field of radiology.
HeartLung Technologies' AI-CVD platform aligns perfectly with Dr. Henschke's career philosophy. The platform utilizes routine imaging to identify diseases earlier, emphasizing the importance of early intervention. By extracting clinically meaningful cardiovascular and multisystem insights from existing CT scans, HeartLung's AI-enabled solutions empower physicians to turn routine imaging into a powerful tool for risk detection and prevention.
Dr. Morteza Naghavi, Founder and CEO of HeartLung Corporation, expressed his admiration for Dr. Henschke's work, stating, 'Dr. Henschke’s recognition with the Jacobi Medallion is a well-deserved honor for one of the most influential leaders in medical imaging and early disease detection.'
HeartLung Technologies is committed to advancing early detection, medical imaging, and patient-centered innovation, and Dr. Henschke's leadership and vision continue to inspire the company's future endeavors. Her dedication to early disease detection and preventive medicine has left an indelible mark on the medical community, and her work will undoubtedly continue to shape the future of healthcare.
